PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34523693-0	2021	Triamcinolone acetonide modulates TGF-beta2-induced angiogenic and tissue-remodeling effects in cultured human retinal pigment epithelial cells.	Triamcinolone Acetonide	0-23	transforming growth factor beta 2	Homo sapiens	34-43	
34523693-8	2021	TA treatment exhibited no prominent cytotoxicity but markedly antagonized TGF-beta2-induced cytostatic effects on RPE cell viability and TGF-beta2-enhanced contractility in collagen gels.	Triamcinolone Acetonide	0-2	transforming growth factor beta 2	Homo sapiens	74-83	
34523693-8	2021	TA treatment exhibited no prominent cytotoxicity but markedly antagonized TGF-beta2-induced cytostatic effects on RPE cell viability and TGF-beta2-enhanced contractility in collagen gels.	Triamcinolone Acetonide	0-2	transforming growth factor beta 2	Homo sapiens	137-146	
34523693-9	2021	In the context of TGF-beta2-related signaling, TA significantly attenuated TGF-beta2-elicited Smad2, extracellular-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation.	Triamcinolone Acetonide	47-49	transforming growth factor beta 2	Homo sapiens	18-27	
34523693-10	2021	Moreover, TA markedly mitigated TGF-beta2-induced VEGF upregulation through ablation of p38 signaling activity.	Triamcinolone Acetonide	10-12	transforming growth factor beta 2	Homo sapiens	32-41	
34523693-11	2021	TA also partially attenuated TGF-beta2-elicted expression of COL1A1, alpha-SMA, MMP-2, and MMP-9, but only suppressed TGF-beta2-induced MMP-9 gelatinolytic activity.	Triamcinolone Acetonide	0-2	transforming growth factor beta 2	Homo sapiens	29-38	
34523693-11	2021	TA also partially attenuated TGF-beta2-elicted expression of COL1A1, alpha-SMA, MMP-2, and MMP-9, but only suppressed TGF-beta2-induced MMP-9 gelatinolytic activity.	Triamcinolone Acetonide	0-2	transforming growth factor beta 2	Homo sapiens	118-127	
34523693-13	2021	In conclusion, TA may be considered a useful therapeutic agent for treating TGF-beta2-associated intraocular angiogenesis and tissue remodeling, the underlying mechanism of which may involve the ERK and p38 MAPK signaling pathways.	Triamcinolone Acetonide	15-17	transforming growth factor beta 2	Homo sapiens	76-85